Antimicrobial treatment and outcomes of critically ill patients with OXA-48like carbapenemase-producing Enterobacteriaceae infections.

Abstract

We report on the clinical characteristics, antimicrobial therapy, and outcomes of 20 critically ill patients with severe OXA-48like infections. Carbapenem-based therapy demonstrated improved survival (odds ratio = 5.0) as compared with non-carbapenem therapy. Risk factors for mortality included Acute Physiology and Chronic Health Evaluation III score and length of stay, highlighting the significant influence of comorbidities and severity of underlying illness on outcomes.

• Authors: Warren Lowman, Gunter Schleicher
• Journal: Diagnostic microbiology and infectious disease (Diagn Microbiol Infect Dis) Vol. 81 Issue 2 Pg. 138-40 (Feb 2015) ISSN: 1879-0070 [Electronic] United States
• PMID: 25497419 (Publication Type: Journal Article)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Chemical References

• Anti-Bacterial Agents
• Bacterial Proteins
• Carbapenems
• beta-Lactamases
• carbapenemase

Topics

• Adult
• Aged
• Aged, 80 and over
• Anti-Bacterial Agents (therapeutic use)
• Bacterial Proteins (metabolism)
• Carbapenems (therapeutic use)
• Critical Illness
• Enterobacteriaceae (enzymology, isolation & purification)
• Enterobacteriaceae Infections (drug therapy, microbiology, mortality)
• Female
• Humans
• Male
• Middle Aged
• Retrospective Studies
• Survival Analysis
• Treatment Outcome
• Young Adult
• beta-Lactamases (metabolism)